Spotlight On... Sanofi, Regeneron rack up some cost-savings data for their PCSK9 contender Praluent; PhRMA goes on an image offensive; Biogen readies Lantus biosim in Japan; China needs to cut dependence on imported meds, drugmaker says; and more...

It's not the cardiovascular outcomes data doctors and payers are waiting for, but it's outcomes data nonetheless. Sanofi ($SNY) and Regeneron's ($REGN) PCSK9 contender Praluent helped patients with a severe form of high cholesterol cut back on pricey and cumbersome aphaeresis treatments, new late-stage study data show. More from FiercePharmaMarketing

@FiercePharma: Intersections snags $20M loan to support struggling Voyce health monitor for dogs. FierceAnimalHealth report | Follow @FiercePharma

@CarlyHFierce: ICYMI: With Cinqair nod, Teva squares off with GSK in severe asthma. Article | Follow @CarlyHFierce

> Steve Ubl, the new CEO of PhRMA, says the lobbying group will take an offensive, rather than defensive, approach to facing issues like concern over pharma price increases. Story

> India's Biocon has gotten approval from Japan for its biosimilar of Sanofi's ($SNY) Lantus, a step Managing Director Kiran Mazumdar-Shaw called a "credibility milestone" for the company. Story

> A Chinese drugmaker says the country needs more homegrown drugs to reduce its dependence on imports. Report

> A study says the risk of death goes way up for patients with Parkinson's disease who are treated with antipsychotic drugs. Blog Post

Medical Device News

@FierceMedDev: ICYMI: Philips shells out $35M to settle sleep apnea mask kickback charges with DOJ. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Medtronic to stop manufacturing some devices in Colorado in pursuit of $850M in promised synergies. Article | Follow @VarunSaxena2

@EmilyWFierce: Valeant's wounds bleed onto Ackman's Pershing Square with latest Senate probe. FiercePharma story | Follow @EmilyWFierce

> Ex med tech CEO faces jail time for bribing docs to promote skin-like wound dressing. Report

> Goldman Sachs invests $37M in Chinese TAVR player. Story

> Fed judge rules case against Bayer's Essure birth control device to move forward. Article

Biotech News

@FierceBiotech: UPDATED: FDA's internal review of Acadia's Parkinson's drug raises safety, benefit concerns. Article | Follow @FierceBiotech

@JohnCFierce: From the weekend bureau: Forum faces the end o' the road. Story | Follow @JohnCFierce

> Alder rockets up as promising migraine data heats up a frenzied race for CGRP drug approval. Story

> Under pressure, XenoPort sells U.S. rights of failed psoriasis pill to Dr. Reddy's. Article

> Aduro offers $7.5M to fuel UC Berkeley's immunotherapy research effort. More

Animal Health News

> Akorn emerges from audit with better-than-expected 2015 results. Item

> Neogen plunges on Q3 miss as CEO seeks global growth for gene-testing services. Article

> Genes in canine bone tumors predict drug response: Report. More

> Intersections snags $20M loan to support struggling Voyce health monitor for dogs. News

> Roslin turns to business with new animal health venture. Report

Biotech IT News

> Lundbeck upgrades ArisGlobal regulatory and safety IT system. Item

> 23andMe tech brings genetic data to Apple ResearchKit studies. More

> Overturning bioinformatic predictions, Venter creates minimal synthetic cell with 473 genes. Story

> Sony-backed M3, Endeavour Vision unveil digital health investment funds. Article

> Microsoft co-founder commits $100M to early-stage research at intersection of IT and biology. Report

Pharma Marketing News

> Looking for a respiratory edge, Boehringer teams with Propeller to test 'smart inhaler' for adherence. Article

> Apple's CareKit opens new door for pharma to develop apps, but will it walk through? More

> Could J&J get an image boost from new health-oriented research? Experts say yes. Story

> Novartis kickbacks blows up as feds demand info on 80,000 doc events. Item

And Finally... During a trip to Cuba, Pfizer's Dave Verbraska, VP of worldwide public affairs, found state-run pharmacies, domestically produced generic drugs and few imports. Blog Post

Suggested Articles

With generics at the gates, Novartis’ Gilenya secured a breath of fresh air—and protection for its blockbuster sales—with a federal injunction.

Akorn has been slammed with another FDA warning letter even as it is in the process of renegotiating its loans with lenders.

Horizon Therapeutics is preparing for the potential launch of inflammatory eye drug teprotumumab with team building.